
Opinion|Videos|December 26, 2023
Emerging Bispecifics in the Treatment Paradigm for R/R LBCL
Author(s)Frederick Locke, MD
Expert discusses the emergence of recently approved bispecific antibodies in R/R LBCL, emphasizing the importance of toxicity management for adverse events such as cytokine release syndrome (CRS).
Advertisement
Episodes in this series

Advertisement
Related to this article

The anti-CD19/CD20 CAR T-cell therapy will be studied in the phase 2 ABZT-121 trial after progression on commercial CAR T-cell therapy.

Read a refresh of hematologic cancer FDA news from October 2026, including the approval of a noncovalent BTK inhibitor in untreated CLL/SLL.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Giredestrant Plus Everolimus for ER+/HER2–, ESR1-Mutated Metastatic Breast Cancer
2
Daraxonrasib Gains EC Approval in Previously Treated Metastatic Pancreatic Cancer
3
Pertuzumab Biosimilar Gains FDA Approval for HER2+ Breast Cancer
4
Cretostimogene Grenadenorepvec Improves RFS in Intermediate-Risk and High-Grade Ta NMIBC
5


